The benefits of intermittent oral iron supplementation plus folic acid are similar to those of daily supplementation in terms of maternal and infant outcomes, according to the results of a recent systematic analysis.
The benefits of intermittent oral iron supplementation plus folic acid are similar to those of daily supplementation in terms of maternal and infant outcomes, according to the results of a recent systematic analysis.1
Daily iron supplementation throughout pregnancy has been the traditional treatment of gestational anemia. However, poor adherence because of adverse effects, supply interruptions, and safety concerns has limited the use of this practice. To help reduce the adverse effects associated with daily iron supplementation, which include constipation and nausea, and to increase ease of use of the regimen, intermittent supplementation of iron-1 to 3 times per week on nonconsecutive days-has been proposed. In this new review study, researchers evaluated the benefits and harms of intermittent oral iron supplementation alone or with folic acid or other vitamins and minerals on neonatal and pregnancy outcomes.
The researchers used data from 18 trials that included a total of 4072 women. All of the included trials compared daily iron supplementation with intermittent iron supplementation. Three studies included data for iron supplementation alone, 12 studies included data on iron plus folic acid, and 3 studies focused on iron plus vitamins and minerals.
Analysis of the available data revealed no clear differences between trial groups for neonatal primary outcomes, including mean infant birthweight and rates of low birthweight and premature birth. Neonatal deaths and congenital anomalies were not reported in any of the studies. In addition, there was no clear evidence of any differences in the rates of maternal anemia at term.
Compared with daily supplementation, intermittent supplementation was associated with fewer adverse effects and a lower risk of having a high hemoglobin concentration (more than 130 g/L) in the second or third trimester. Among women receiving any type (daily or intermittent) of supplementation with iron plus folic acid, no differences in the rates of iron-deficiency anemia were found.
Overall, the evidence for use of intermittent iron supplementation is limited and the quality of what little evidence exists is poor. However, this new review provides the most comprehensive summary of the evidence evaluating the benefits and harms of intermittent iron supplementation to date, according to the study authors. Considering the available evidence, the study authors conclude that intermittent iron supplementation may be a feasible alternative to daily iron supplementation among pregnant women who are not otherwise anemic and who have adequate medical care.
Pertinent Point:
- Intermittent iron supplementation, compared with daily supplementation, may decrease the likelihood of high hemoglobin concentrations occurring in mid and late pregnancy, which potentially decreases the risk of premature birth and having a small-for-gestational-age neonate.
1. Pena-Rosas JP, De-Regil LM, Dowswell T, Viteri FE. Intermittent oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2012;7:CD009997.
S1E4: Dr. Kristina Adams-Waldorf: Pandemics, pathogens and perseverance
July 16th 2020This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.
Listen
Similar delivery times between misoprostol dosages among obese patients reported
May 29th 2024A recent study found that obese patients undergoing induction of labor experienced similar delivery times regardless of whether they received 50 μg or 25 μg of vaginal misoprostol, though multiparous patients showed faster delivery with the higher dosage.
Read More
Buprenorphine use in pregnancy linked to decreased fetal breathing movements
May 18th 2024According to a poster presented at ACOG 2024, use of the synthetic opioid buprenorphine depressed fetal breathing in biophysical profile assessments, but had no significant impact on other factors like amniotic fluid index or fetal tone.
Read More